Sep. 3 at 6:59 PM
$ADMA ADMA Biologics is a U.S.-based biopharmaceutical company specializing in plasma-derived biologics for immune deficiencies and infectious diseases, with products like ASCENIV, BIVIGAM, and Nabi-HB.
CEO Adam Grossman leads the company with a focus on commercial growth and manufacturing innovations for yield enhancement.
Q2 2025 revenue reported was
$122.0 million, a 14% YoY increase, with accelerated growth expected in H2 2025 and beyond.
TAM is estimated at over
$1.1 billion prior to 2030 for its specialty biologics market, reflecting demand in rare immunodeficiency and infectious diseases.
SAM, considering current commercial scale and payer dynamics, is effectively around
$500–600 million in near term.
Conservative peak sales are projected at approximately
$1 billion by late 2020s, factoring new manufacturing yield improvements and product adoption.
Market capitalization as of September 2025 is around
$4.12 billion, with shares outstanding approx. 241 million.
